Cannabidiol formulations

A pharmaceutical composition a pharmaceutically acceptable carrier and a spray dried powder comprising:

• (i) 30-45 wt.-%, based on the total weight of the spray dried powder, of cannabidiol,
• (ii) 5 to 15 wt.-%, based on the total weight of the spray dried powder, of Vitamin E,
• (iii) 2.5 to 7.5 wt.-%, based on the total weight of the spray dried powder, of tocopherol polyethylene glycol succinate,
• (iv) 25 to 40 wt.-%, based on the total weight of the spray dried powder, of gelatine,
• (v) 4 to 10 wt.-%, based on the total weight of the spray dried powder, of hydrolysed starch having a DE value selected in the range of 8 to 38,
• (vi) 0.5 to 3 wt. %, based on the total weight of the spray dried powder, of an additional antioxidant (other than Vitamin E), and
• (vii) less than 5 wt.-%, based on the total weight of the spray dried powder, of water,
• wherein the spray dried powder further comprises cannabidiol hydroxyquinone in an amount of up to 0.5 wt.-%, based on the total amount of the spray dried powder.

A method of treating a disease or disorder that benefits from cannabidiol therapy in a patient in need thereof, comprising administering to the patient a therapeutically effective dose of a pharmaceutical composition comprising:

• (i) about 20 to 50 wt.-%, based on the total weight of the composition, of cannabidiol or a pharmaceutically acceptable salt thereof;
• (ii) about 1 to 25 wt.-%, based on the total weight of the composition, of Vitamin E;
• (iii) about 1 to 15 wt.-%, based on the total weight of the composition, of a Vitamin E Derivative;
• and
• (iv) one or more excipients or additives in an amount to make the composition total 100 wt.-%;
• wherein the composition is administered with or without food and without regard to the proximity of a meal.